Biogen Pays $900M to Settle Doctor Kickback Allegations
Biogen Pays $900M to Settle Doctor Kickback Allegations

BOSTON (AP) — Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors to persuade them to prescribe its multiple sclerosis drugs, federal prosecutors said. The agreement announced Monday settles... Read More

Prescription Drugs
FDA Changes Prescribing Instructions for Controversial Alzheimer’s Drug
2021-07-08 17:38:20
by Dan McCue

U.S. health regulators on Thursday approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer’s drug. The announcement came through Biogen Inc., the maker of Aduhelm, which stated the update is intended to “clarify” the... Read More

FDA Approves Controversial Alzheimer’s Drug Despite Potential Harm
2021-06-07 19:38:35
by Reece Nations

SILVER SPRING, Md. — The Food and Drug Administration on Monday granted its approval to aducanumab, an Alzheimer’s treatment developed by Biogen for use in patients, despite mixed clinical trial results for the drug.  Prescribed under the brand name “Aduhelm,”... Read More

Straight From The Well